Tumor angiogenesis: Current challenges and therapeutic opportunities.
Tumor angiogenesis: Current challenges and therapeutic opportunities.
复制标题
DOI：
10.1016/j.ctarc.2021.100422
复制
发表时间：
2021-01-01
影响因子：
--
通讯作者：
Khanum, Shaukath Ara
中科院分区：
文献类型：
--
作者：
Al-Ostoot, Fares Hezam;Salah, Salma;Khanum, Shaukath Ara
血管生成在癌症的发展中起着重要作用，因为它允许氧气、营养物质和生长因子的输送，以及肿瘤向远处器官的扩散。抑制血管生成是预防多发性实体瘤的重要策略，这些实体瘤依赖于切除或至少减少肿瘤微区的血液供应，导致实体瘤组织内泛缺氧和泛坏死。这些药物是治疗某些类型癌症的重要组成部分。作为一种单独的治疗方法，抑制肿瘤血管生成可以阻止或阻止肿瘤的生长，但不能消除肿瘤。因此，抗血管生成药物与另一种抗癌治疗方法(如化疗)联合使用，对于癌症患者的最佳预后至关重要。在过去的二十年里，为了提高抗血管生成药物的疗效，认识到它们在药物相互作用中的潜力，并对可能的治疗耐药性提出了可信的解释，人们进行了研究。本文将对肿瘤血管生成的不同概念、几种重要的血管生成因子进行综述，重点介绍抗血管生成策略在肿瘤治疗中的作用。
Angiogenesis plays an important role in the development of cancer since it allows for the delivery of oxygen, nutrients, and growth factors as well as tumor dissemination to distant organs. Inhibition of angiogenesis is an important strategy for the prevention of multiple solid tumors that depend on cutting or at least reducing the blood supply to tumor micro-regions, resulting in pan-hypoxia and pan-necrosis within solid tumor tissues. These drugs are an important part of treatment for some types of cancer. As a stand-alone therapy, inhibition of tumor angiogenesis can arrest or halt tumor growth, but will not eliminate the tumor.Therefore, anti-angiogenic drugs in combinations with another anti-cancer treatment method, like chemotherapy, lead to being critical for optimum cancer patient outcomes. Over the last two decades, investigations have been made to improve the efficacy of anti-angiogenic drugs, recognize their potential in drug interactions, and come up with plausible explanations for possible treatment resistance. This review will offer an overview of the varying concepts of tumor angiogenesis, several important angiogenic factors; focus on the role of anti-angiogenesis strategies in cancer treatment.